Pearl Cohen advised Chiasma on the set-up and management of its phase III.
The FDA approved Chiasma Inc.’s MYCAPSSA® (octreotide) capsules for oral treatment of acromegaly, utilizing Chiasma’s Transient Permeability Enhancer (TPE®) technology.
Chiasma, Inc. operates as a biopharmaceutical company, and develops pharmaceutical products for the treatment of acromegaly and hormonal disorders.
The Pearl Cohen team was led by Michal Rom (Picture).
Involved fees earner: Michal Rom – Pearl Cohen;
Law Firms: Pearl Cohen;
Clients: Chiasma, Inc;